Western biomedicine and Eastern therapeutics an integrative strategy for personalized and preventive healthcare - Wang, Sun-Chong (World Scientific Pub. Co., 2013)
Includes bibliographical references (pages 339-346) and index
Ch. 1. Evidence-based practice. 1.1. The FDA drug approval process. 1.2. Randomized controlled trial. 1.3. Level of evidence. 1.4. Cochrane review. 1.5. Drug development. 1.6. Translational medicine -- ch. 2. Modern western biomedicine. 2.1. ATP hydrolysis. 2.2. Oxidative phosphorylation, the electron transport chain, the Krebs cycle. 2.3. Glycolysis, aerobic respiration, the Warburg effect. 2.4. Reactive oxygen species, oxidative stress, redox signaling. 2.5. Cell metabolism. 2.6. The central dogma of molecular biology, the genome. 2.7. Eukaryotic cell division cycle. 2.8. Meiosis, Mendelian inheritance, genetic disorder. 2.9. Chromatin modification, complex disorder. 2.10. Immunity, hematopoiesis -- ch. 3. Traditional oriental ethnomedicine. 3.1. Ayurveda. 3.2. Asana, pranayama, dhyana. 3.3. Traditional Chinese medicine. 3.4. Acupuncture --
- ch. 4. Integrative medicine. 4.1 Bioenergetics, tridosha, chronic disorder. 4.2 Complex adaptive system, yogic cognitive-behavioral practice, psychological stress management. 4.3 Placebo effect, acupuncture analgesia, chronic pain. 4.4 Periodontitis: an example of holistic therapy. 4.5 Practical clinical trial for the effectiveness of integrative therapy -- ch. 5. Safety and regulation of herbal products. 5.1. Plant secondary metabolites. 5.2. Pharmacodynamic and pharmacokinetic herb-drug interactions. 5.3. Regulation of TCM and other natural herbal products in China. 5.4. Kampo medicine in Japan. 5.5. Regulation of TCM medicine in Taiwan. 5.6. Regulation of natural health products in Canada. 5.7. Botanical products as dietary supplements in the United States. 5.8. Regulation of traditional herbal medicinal products in the European Union --
- ch. 6. Cancer. 6.1. Six core and two emerging hallmarks of cancer. 6.2. Mechanisms of hallmark acquisition: genomic and epigenomic instability, inflammation; microenvironment. 6.3. Frontiers of conventional treatment: drug cocktail cotargeting multiple hallmarks; personalized targeted therapy. 6.4. TCM carbuncle-treating, TCM mediating formulas; TCM cold herbs against neoplasms. 6.5. Uterine leiomyoma: Gui Zhi Fu Ling Wan and Yi Mu Cao. 6.6. Benign nonfibroid neoplasm of the uterus: Gui Zhi Fu Ling Wan and E Shu. 6.7. Benign neoplasm of the ovary: Gui Zhi Fu Ling Wan and Yi Mu Cao. 6.8. Benign neoplasm of the thyroid gland: San Zhong Kui Jian Tang and Xia Ku Cao. 6.9. Benign neoplasm of the breast: Jia Wei Xiao Yao San and Pu Gong Ying. 6.10. Lipoma: San Zhong Kui Jian Tang and Bai Jie Zi. 6.11. Benign neoplasm of male genital organs: Ji Sheng Shen Qi Wan and Che Qian Zi. 6.12. Benign neoplasm of the lower GI tract digestive system: Ban Xia Xie Xin Tang and Yan Hu Suo. 6.13.
- Carcinoma in situ of the breast and genitourinary system: Ji Sheng Shen Qi Wan and Pu Gong Ying. 6.14. Benign neoplasm of the brain and other parts of the nervous system: Zhen Ren Huo Ming Yin and Bei Mu. 6.15. Malignant neoplasm of the female breast: Jia Wei Xiao Yao San and Pu Gong Ying